In addition, this group of patients also showed upregulation of CD79b. Chronic active BCR signaling due to point mutations in CD79b has recently been identified as a key pathogenic mechanism in aggressive B-cell lymphoma, and results in constitutive nuclear factor-kB (NF-kB) activation [30]. The gene discussed is NFKB1; the disease is B-cell non-Hodgkin lymphoma.